Myc-dependent apoptosis as a tumor-suppressive mechanism: how do cells discriminate between physiological and oncogenic levels of Myc expression?

Myc 依赖性细胞凋亡作为肿瘤抑制机制:细胞如何区分 Myc 表达的生理水平和致癌水平?

基本信息

项目摘要

Deregulated expression of Myc is observed in the majority of all human tumors and is universal in some tumor entities. A plethora of tissue culture and transgenic experiments documents that deregulated expression of Myc elicits multiple characteristics of transformed cells and contributes to tumorigenesis. Surprisingly, ectopic expression of Myc in primary cells induces apoptosis and this is thought to be a major failsafe mechanism that protects organisms from tumorigenesis. Current concepts suggest that tumors can only arise when secondary mutations block Myc-induced apoptosis. Despite many studies, the molecular mechanisms that allow cells to discriminate physiological from supra-physiological levels of Myc remain unresolved.Myc proteins are transcription factors that bind to the majority of open promoters in the genome. Some models assume that all binding sites are functionally equivalent and see Myc proteins as universal "amplifiers" of transcription. This contrasts with experiments showing that Myc activates and represses specific genes.We have shown previously that Myc forms a complex with the Zn-finger protein Miz1 and inhibits Miz1-dependent transcription. This is critical for Myc-induced tumorigenesis. We have now performed extensive ChIp-sequencing and found that Miz1 co-binds the majority of Myc target promoters; hence, target promoters of Myc bind a mixture of activating and repressive complexes. We have identified the consensus Miz1 binding sequence and shown that Myc and Miz1 recruit each other to their cognate target sites. As a result, the topology, relative proportion of Myc and Miz1 bound, and the response to Myc differs among promoters. The resulting model sees Myc as a specific regulator of transcription rather than a general transcriptional amplifier.Genes with consensus Miz1 binding motifs sites are not targets for repression by Myc. Promoters of repressed genes are characterized by the absence of consensus E-boxes and Miz1 binding motifs and by binding relatively low amounts of both proteins, suggesting that their occupancy changes with varying Myc levels. In a parallel work, we have found that induction of apoptosis by Myc in epithelial cells depends on association of Myc with Miz1 and identified a group of genes that are regulated by Myc in a Miz1-dependent manner. These genes are required for epithelial cell integrity and Myc specifically suppresses growth of epithelial, but not of stem cells. Strikingly, these genes are selectively regulated in response to supra-physiological levels of Myc. Collectively, the data suggest that the relative affinities of Myc/Miz1 complexes to different target promoters allow cells to discriminate physiological from supra-physiological levels of Myc. Here we propose to test this hypothesis and study the underlying biochemical mechanisms. We believe that this study will open the way for a biochemical and, ultimately, quantitative understanding of Myc-induced apoptosis.
在大多数人类肿瘤中观察到MYC的放松调节表达,并且在某些肿瘤实体中是普遍的。大量的组织培养和转基因实验证明,放大MYC表达的调节,引起了转化细胞的多种特征,并导致肿瘤发生。出乎意料的是,MYC在原代细胞中的异位表达诱导凋亡,这被认为是保护生物免受肿瘤发生的主要故障安全机制。当前的概念表明,只有当次要突变阻断MYC诱导的细胞凋亡时才能产生肿瘤。尽管进行了许多研究,但允许细胞将生理学与MYC上生理学水平区分开的分子机制尚未解决。MyC蛋白是与基因组中大多数开放启动子结合的转录因子。一些模型假设所有结合位点在功能上都是等效的,并且将MYC蛋白视为转录的通用“放大器”。这与表明MYC激活并抑制特定基因的实验形成对比。我们先前表明MYC与Zn Finger蛋白Miz1形成复合物,并抑制MIZ1依赖性转录。这对于MYC诱导的肿瘤发生至关重要。现在,我们已经进行了广泛的芯片测序,发现MIZ1共同结合了大多数MYC目标启动子。因此,MYC的靶启动子结合了激活和抑制性复合物的混合物。我们已经确定了共有的MIZ1结合序列,并表明MYC和MIZ1相互募集到其同源目标位点。结果,MYC和MIZ1结合的拓扑,相对比例以及对MYC的反应在启动子之间有所不同。所得模型将MYC视为转录的特定调节剂,而不是一般的转录放大器。具有共识MIZ1结合基序位点位点的基因不是MYC抑制的目标。被抑制基因的启动子的特征是没有共识E盒和Miz1结合基序以及两种蛋白质相对较低的结合,表明它们的占用率随着MYC水平的变化而变化。在平行的工作中,我们发现MYC在上皮细胞中诱导凋亡取决于MYC与MIZ1的关联,并确定了一组由MYC以MIZ1依赖性方式调节的基因。这些基因是上皮细胞完整性所必需的,MYC专门抑制上皮的生长,但不抑制干细胞的生长。令人惊讶的是,这些基因根据MYC的上生物学水平有选择地调节。总体而言,数据表明,MYC/MIZ1复合物与不同靶启动子的相对亲和力使细胞可以区分生理学与MYC的上生物学水平。在这里,我们建议检验这一假设并研究潜在的生化机制。我们认为,这项研究将为MYC诱导的细胞凋亡的生化,最终定量理解开辟道路。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Repression of SRF target genes is critical for Myc‐dependent apoptosis of epithelial cells
  • DOI:
    10.15252/embj.201490467
  • 发表时间:
    2015-06
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Katrin E. Wiese;Heidi M. Haikala;B. Eyss;E. Wolf;C. Esnault;A. Rosenwald;R. Treisman;J. Klefström;M. Eilers
  • 通讯作者:
    Katrin E. Wiese;Heidi M. Haikala;B. Eyss;E. Wolf;C. Esnault;A. Rosenwald;R. Treisman;J. Klefström;M. Eilers
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Martin Eilers其他文献

Professor Dr. Martin Eilers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Martin Eilers', 18)}}的其他基金

Targeting MYC-driven hepatocellular carcinoma via Aurora-A ligands
通过 Aurora-A 配体靶向 MYC 驱动的肝细胞癌
  • 批准号:
    409494652
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Research Units
ShRNA Screening and Histopathology
ShRNA 筛选和组织病理学
  • 批准号:
    280454646
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Research Units
Targeting MYC in pancreatic cancer
靶向 MYC 治疗胰腺癌
  • 批准号:
    280452953
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Research Units
Systematic shRNA screens for the analysis of critical signaling pathways in KRAS-mutant multiple myeloma
系统性 shRNA 筛选分析 KRAS 突变型多发性骨髓瘤的关键信号通路
  • 批准号:
    242271643
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units
Systemic shRNA screens and high throughout sequencing to investigate pathway dependence in multiple myeloma
系统 shRNA 筛选和高通量测序以研究多发性骨髓瘤的通路依赖性
  • 批准号:
    144856378
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units
Systematic shRNA and siRNA screens to investigate drug resistance in human leukemia
系统性 shRNA 和 siRNA 筛选研究人类白血病的耐药性
  • 批准号:
    81569355
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units
Role of Miz1 in the Atr/Chk1 signalling pathway and in Myc-induced apoptosis
Miz1 在 Atr/Chk1 信号通路和 Myc 诱导的细胞凋亡中的作用
  • 批准号:
    5422428
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:
    Research Units
Rolle des Zink-Finger-Proteins Miz-1 in der Tumorigenese und in der Kontrolle der Proliferation von Keratinozyten und Lymphozyten
锌指蛋白 Miz-1 在肿瘤发生以及角质形成细胞和淋巴细胞增殖控制中的作用
  • 批准号:
    5340710
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Regulation of the cdk inhibitor, p27 Regulation des cdk inhibitor, p27
cdk 抑制剂的调节,第 27 页 cdk 抑制剂的调节,第 27 页
  • 批准号:
    5224632
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
    Priority Programmes
MYCN-dependent Transcription Termination and Stress Resilience of Transcription
MYCN依赖性转录终止和转录的应激恢复能力
  • 批准号:
    438596161
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

RIG-I/MAVS非干扰素依赖通路诱导细胞凋亡介导七鳃鳗抗病毒的机制研究
  • 批准号:
    32360150
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
基于piezo1通道门控作用探讨电针大肠俞募穴调控慢传输型便秘大鼠Cajal间质细胞线粒体依赖性凋亡机制
  • 批准号:
    82374595
  • 批准年份:
    2023
  • 资助金额:
    45 万元
  • 项目类别:
    面上项目
NLK经内质网应激ATF6/CHOP途径调控Caspase-8依赖的小胶质细胞泛凋亡在脓毒症相关性脑病中的作用研究
  • 批准号:
    82371370
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
结核分枝杆菌Rv2569c半胱氨酸蛋白酶介导Caspase非依赖性巨噬细胞凋亡的机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
结核分枝杆菌Rv2569c半胱氨酸蛋白酶介导Caspase非依赖性巨噬细胞凋亡的机制研究
  • 批准号:
    32273005
  • 批准年份:
    2022
  • 资助金额:
    54.00 万元
  • 项目类别:
    面上项目

相似海外基金

Novel functions of CDK6 in T-cell leukemia progression
CDK6 在 T 细胞白血病进展中的新功能
  • 批准号:
    10297128
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Novel functions of CDK6 in T-cell leukemia progression
CDK6 在 T 细胞白血病进展中的新功能
  • 批准号:
    10670263
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Novel functions of CDK6 in T-cell leukemia progression
CDK6 在 T 细胞白血病进展中的新功能
  • 批准号:
    10456933
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
靶向转录组失调作为骨髓增殖后肿瘤 (MPN) sAML 的治疗方法
  • 批准号:
    10595080
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Myc Physiology in the Pancreatic Beta Cell
胰腺 Beta 细胞中的 Myc 生理学
  • 批准号:
    10224945
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了